Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Biotech startups are built on venture capital. Track funding rounds ...
Nov 21, 2024 · Drug development is an expensive, risky endeavor. Biotechnology companies just starting out are many years away from seeing profits, if ever. So more often than not, a startup’s success turning science into medicines can come down to how much money it raises.
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
Nov 22, 2024 · Notably, the drug is approved to prevent hospitalization or death resulting from heart complications of transthyretin amyloidosis with cardiomyopathy. Investors had been skeptical BridgeBio would earn such a distinction from regulators, leading to doubts about Attruby’s commercial prospects.. BridgeBio priced Attruby at just under $19,000 for a 28-day supply, translating to an annual list ...
Drug patents protect pharma profits. Track when they’ll expire.
May 8, 2024 · Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay for many years, even decades, and allows pharmaceutical companies to set higher prices than they otherwise could.
Novo’s next-gen obesity drug misses expectations in closely …
Dec 20, 2024 · The trial results announced Friday are a blow to Novo’s o besity ambitions, then, disappointing analysts and investors eager for signs it can continue to dominate a drug class projected to eventually surpass $100 billion in yearly sales. David Risinger, an analyst with Leerink Partners, wrote that, in light of the findings, “it …
Merck calls quits on two immunotherapies for cancer
Merck & Co. on Dec. 16, 2024, cancelled work on combination therapies with its cancer drug Keytruda. Sundry Photography via Getty Images
Novartis wagers more than $1B on gene therapies for the nervous …
Nov 21, 2024 · The Kate acquisition comes almost a year and a half after Novartis agreed to buy DTx Pharma, a startup aiming to use RNA drugmaking technology to treat neurological diseases. The deal, which carried a $500 million upfront payment, handed Novartis a few experimental drugs that had yet to reach human testing.
The biopharma industry outlook on 2024: Guarded optimism for a …
Jan 16, 2024 · Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024.. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a more strident Federal Trade Commission, further weighed on the sector.. There are now some signs of a turnaround, from a rebounding ...
Biotech M&A has plateaued. Track the deals that are happening …
Jan 13, 2025 · Methodology. For this database, BioPharma Dive looked only at companies developing human medicines. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company — not for product licensings, options to acquire or for partial equity stakes.
AbbVie to acquire a J&J-backed brain drugmaker for $1.4B
Oct 28, 2024 · AbbVie has agreed to acquire a young company with drugmaking technology from Johnson & Johnson and an experimental treatment for Alzheimer’s disease that’s in the first stage of human testing.. The deal, announced Monday, is expected to close by the end of the year, and has AbbVie buying all the outstanding shares of Aliada Therapeutics for $1.4 billion in cash.